William Andrew Macan - listed as Executive Vice President, CLO and CS at Neuronetics, Inc. (NASDAQ:STIM) - executed a sale of 3,427 shares of Neuronetics common stock on February 26, 2026. The disposition was completed at a weighted average price of $1.35 per share, producing total proceeds of $4,626.
The individual trade prices for the shares ranged from $1.31 to $1.38. Company disclosures state the sale was made to satisfy tax obligations arising from the vesting of restricted stock units. After the transaction, Macan is reported to directly hold 880,134 Neuronetics shares.
At the time of the sale, Neuronetics shares had been trading in proximity to their 52-week low of $1.20. The stock had, however, experienced a roughly 10% rebound over the preceding week.
Company financials and executive awards
Neuronetics released notable preliminary unaudited financial results for the 2025 fourth quarter and full year. The company reported fourth-quarter revenue of $41.8 million, representing an 86% year-over-year increase on a preliminary unaudited basis. For the full year 2025, Neuronetics recorded revenue of $149.2 million, a 99% increase compared with the prior year.
Alongside the revenue disclosures, the company announced board-approved annual cash incentive awards for several senior executives. The board approved $412,775.95 for Chief Executive Officer Keith J. Sullivan, $163,383.75 for Chief Legal Officer W. Andrew Macan, and $73,216.44 for Chief Financial Officer Steven E. Pfanstiel.
Additional compensation awards were also disclosed. According to the information released, Steven E. Pfanstiel received a $240,000 cash award and 170,212 restricted stock units. W. Andrew Macan was granted a $231,750 cash award and 164,361 restricted stock units. The company characterized these awards in the context of its performance results.
Market context and third-party perspective
InvestingPro analysis, as noted in company-related commentary, indicates that Neuronetics may be undervalued at the prevailing share price. The platform’s Pro Research Report is cited as a source for more detailed analysis available to subscribers.
Overall, the insider sale recorded on February 26 was narrowly tailored to cover tax liabilities from RSU vesting and occurred in a period when the stock sat close to its 52-week low but had shown a short-term recovery.
Summary of the transaction and disclosures
- Insider: William Andrew Macan, Executive Vice President, CLO and CS
- Securities sold: 3,427 shares of Neuronetics common stock
- Transaction date: February 26, 2026
- Weighted average price: $1.35 per share
- Total proceeds: $4,626
- Price range for shares sold: $1.31 to $1.38
- Shares owned after sale: 880,134
- Reason for sale: to cover tax obligations related to RSU vesting